DEXTER Robot Drives Outpatient Surgery Revolution

LAUSANNE, SWITZERLAND – May 21, 2026 – A quiet revolution is reshaping the landscape of American surgery, moving complex procedures from sprawling hospital campuses to nimble, neighborhood Ambulatory Surgery Centers (ASCs). At the heart of this shift is a new class of surgical technology designed not for the cavernous operating rooms of old, but for the efficient, high-turnover reality of outpatient care. Swiss MedTech firm Distalmotion is at the forefront, reporting significant commercial momentum for its DEXTER® Robotic Surgery System as ASCs across the United States increasingly adopt the platform.

The Outpatient Imperative

For years, robotic surgery has been synonymous with large, expensive systems primarily housed in major hospitals. While revolutionary, the high capital costs, extensive infrastructure requirements, and complex workflows of these legacy platforms created a formidable barrier for ASCs. Yet, the broader healthcare trend is an inexorable march toward outpatient procedures, driven by lower costs, patient convenience, and favorable reimbursement models. The surgical robotics market, projected to more than double to nearly $24 billion by 2031, is seeing its fastest growth within these very centers.

This created a critical market gap: ASCs needed a robotic solution that could deliver the clinical benefits of precision and minimally invasive techniques without the prohibitive economic and logistical baggage. Industry leaders recognize the need for solutions that remove barriers and improve efficiency, not just add more complex machinery to the operating room. This is the environment where Distalmotion is finding fertile ground, with major healthcare organizations like CommonSpirit Health, HonorHealth, and Surgery Partners deploying DEXTER in their affiliated centers.

A Robot Reimagined for Efficiency

Unlike its larger predecessors, the DEXTER system was engineered from the ground up for the ASC environment. It combines the benefits of wristed robotic instruments—which mimic the human hand's dexterity—with a design philosophy centered on practicality and flexibility. Its small, mobile footprint allows it to be wheeled into any existing operating room without costly renovations and easily moved between rooms to maximize utilization, a key metric for any ASC.

The system’s open architecture is another significant departure from the closed-ecosystem models of competitors. It allows surgeons to continue using their preferred visualization systems and advanced energy devices, preventing the need for a complete and costly overhaul of OR technology. Perhaps its most unique feature is a sterile surgeon console. This allows the surgeon to sit next to the patient, enabling seamless transitions between robotic and traditional laparoscopic techniques and facilitating direct communication with the rest of the surgical team.

This practical design is winning over early adopters. “Robotics is necessary for our surgical program to grow, but the economics have always been a barrier," said Cynthia Meaux, Market CEO of Cypress Surgery Center, the first Surgery Partners facility in its region to adopt the system. "With DEXTER, the model finally makes sense and gives us a practical way to build a robotic surgery program while maintaining the efficiency that defines the ASC setting.”

Navigating a Competitive Landscape

Distalmotion enters a market long dominated by Intuitive Surgical's da Vinci system, which holds an estimated 60-65% of the global installed base. Giants like Stryker, with its Mako system for orthopedics, and Medtronic, with its Hugo platform, also command significant market presence. However, Distalmotion's strategy is not one of direct, head-on confrontation. Instead, it's a targeted play focused on the specific, unmet needs of the rapidly expanding soft-tissue surgery market in ASCs.

While incumbents are now adapting their strategies for the outpatient space—sometimes offering refurbished, older-generation systems—Distalmotion's advantage is its purpose-built design. The company is positioning DEXTER as an "ASC-native" platform, a right-sized solution for a segment that prioritizes efficiency and cost-effectiveness above all else. This focus is backed by substantial investor confidence, evidenced by a recent $150 million Series G funding round led by Revival Healthcare Capital, specifically aimed at accelerating its US commercial expansion.

Clinical Validation and Surgeon Embrace

The commercial push is built on a solid foundation of regulatory and clinical validation. After receiving FDA De Novo authorization in late 2024 for inguinal hernia repair—a quintessential outpatient procedure—Distalmotion has rapidly secured further 510(k) clearances. The system is now cleared for laparoscopic cholecystectomy (gallbladder removal) and benign hysterectomy, covering three of the top five most common soft-tissue procedures performed in ASCs.

Surgeons using the system report a surprisingly gentle learning curve. One general surgeon at a major academic medical center noted that it took only about five cases to feel proficient with the system. They praised its suitability for smaller ORs and the significant workflow benefit of the sterile console, which allows them to remain at the patient's bedside without needing to break scrub to adjust the robot or assist directly. This hybrid approach, blending robotic precision with direct manual access, is proving to be a compelling clinical advantage.

This positive real-world feedback is supported by formal clinical studies. A multi-center European study on hysterectomies published in 2025 found DEXTER to be safe and effective, with no conversions to open surgery and a mean docking time of less than four minutes. With a pipeline of further clinical trials underway for procedures like sacrocolpopexy and myomectomy, Distalmotion is signaling its intent to continue expanding the platform's utility, further embedding robotic capabilities into the fabric of everyday community-based surgical care.